Cohen, P. A., Loudig, O., Liu, C., Albanese, J., & Fineberg, S. (2019). The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX(®) Recurrence Score in ER-Positive Invasive Breast Cancers. Front Pharmacol.

Cohen, Pascale A., Olivier Loudig, Christina Liu, Joseph Albanese, a Susan Fineberg. "The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX(®) Recurrence Score in ER-Positive Invasive Breast Cancers." Front Pharmacol 2019.

Cohen, Pascale A., et al. "The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX(®) Recurrence Score in ER-Positive Invasive Breast Cancers." Front Pharmacol 2019.